serviceSupport in the Oncology Area

INTAGE Healthcare answers your research questions and provides insights as a reliable partner with specialized knowledge in the area of oncology.

Cancer is the leading cause of death in Japan. With substantial unmet need, it is one of the most active fields for pharmaceutical drug development. INTAGE Healthcare offers the support of a team dedicated to oncology research that keeps up with the rapid flow of information and diverse needs of pharmaceutical and medical device manufacturers in this area.

  • icon

    Optimizing Research Topics

    We work with our clients to optimize research topics based on our experience and understanding of where the market is headed.

  • icon

    Providing Actionable Insights

    Our service doesn’t end when we deliver the report for a research project. We provide ongoing support to help clients create documents for their internal use and make strategic decisions based on the research findings.

  • icon

    Optimizing Research Methods

    We offer optimized research methods based on our understanding of the unique characteristics of oncology environment in Japan and current and past trends.

Features

Feature 01

Specialized staff

A team of oncology research specialists who keep up with all the latest trends in oncology by attending a broad range of international and domestic medical congresses, conducting their own events, etc.

<Medical Society Participation> We attend domestic and international conferences. Some of the conferences we attend include meetings of Japanese Gastric Cancer Association, Japanese Breast Cancer Society, The Japan Lung Cancer Society, Japanese Society of Hematology, Japanese Society of Medical Oncology, WCLC, ASCO, ASH, ESMO, etc.

Feature 02

Optimized Proposals

Able to conduct research across a wide range of respondent segments including clinicians, key opinion leaders (KOLs), pathologists, oncology nurses, oncology pharmacists and patients/caregivers.
Highly experienced across a range of research methods such as cross-sectional online surveys, viewing facility interviews, non-viewed visit interviews and mail surveys.

Feature 03

Highly experienced

Over 10 years of experience conducting research in the oncology area.
Conduct over 200 oncology-related projects per year.

Experienced across a wide variety of cancers such as head and neck, lung, breast, esophageal, gastric, colorectal, hepatic, biliary tract / gall bladder, pancreatic, bladder, urothelial, prostrate, ovarian, melanoma, soft tissue sarcoma (STS), blood, unknown primary origin and rare cancers.

Service Outline

Research consultancy in the oncology area

Consultancy project examples:

  • Consultancy for a full range of research projects from pre- to post launch for new anti-cancer drugs entering the market
  • Research to obtain holistic insights into a disease from the perspectives of pharmacists, nurses, patients and caregivers
  • Physician segmentation proposals based on research data analysis
  • “War game” interviews and other meaningful / exciting research methods
    Other areas of we have experience covering include market understanding, patient journeys, purchase process, forecasting, etc.

Independent Projects / Syndicated Data

2019

  • Research to Understand the Current Usage and Attitude of CAR-T Therapy in Japan
    • Hematology
    • Office visit interviews
    • n=30 valid completions
    • Research conducted among facilities certified as category 1 or 2 transplant centers by The Japan Society for Hematopoietic Stem Cell Transplantation
  • Research on Multiplex Gene Testing (Next Generation Sequencing: NGS)
    (Phase 1, Phase 2)
    • Physicians who diagnose and treat solid tumor cancers
    • Online survey
    • Approximately 1,300 valid completions
    • Covered 30 types of cancer and 12 types of genetic tests
  • Research on Immuno-oncology Treatment Access for Non-Small Cell Lung Cancer
    • Physicians who diagnose and treat lung cancer (patients who do not have driver mutations like EGFR, ALK, and ROS1)
    • Online survey
    • Approximately 270 valid completions
    • Approximately 750 1st line patient cases
    • Approximately 350 2nd line patient cases

2018

  • Research on Multiple Myeloma (treatment approach by patient and physician type)
    • Hematology
    • Online survey
    • Approximately 200 valid completions
    • Approximately 500 2nd line patient cases
    • Approximately 200 3rd line patient cases
    • RRMM drugs prescribed for various patient types
  • Research on Immuno-oncology Treatment Access and Discontinuation for Non-Small Cell Lung Cancer
    • Physicians who diagnose and treat lung cancer (patients who do not have driver mutations like EGFR, ALK, and ROS1)
    • Online survey
    • Approximately 250 valid completions
    • Non-SQ, driver mutation negative patients

2017

  • Research on Hematological Cancer Patient Volume
    • In-depth understanding of patient volume by disease among hematologists

For further information onINTAGE Healthcare Inc.

If you have any questions or comments, please do not hesitate to contact us.

Contact Us

SHARE

facebooktwitter

INTAGE Healthcare’s Scope of Service